Lu-177-DOTATATE

DRUG2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Gastroenteropancreatico TumorsNeuroendocrine NeoplasmsNeuroendocrine TumorsParagangliomaPheochromocytoma

Phase 1

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

RecruitingNCT04086485

National Cancer Institute (NCI)Gastroenteropancreatico Tumors, Neuroendocrine Neoplasms, Neuroendocrine Tumors

Start: 2022-10-03End: 2028-01-01Target: 56Updated: 2026-04-06

Phase 2

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

RecruitingNCT03206060

National Cancer Institute (NCI)Neuroendocrine Neoplasms, Neuroendocrine Tumors, Paraganglioma +1

Start: 2017-10-10End: 2033-01-01Target: 130Updated: 2026-04-01

Related Papers

An automated pheochromocytoma and paraganglioma lesion segmentation AI-model at whole-body 68Ga- DOTATATE PET/CT

EJNMMI Research2024-11-054 citations

Managing Catecholamine Release Syndrome During and Following Lu-177-DOTATATE in High-Risk Pheochromocytoma Patients

JCEM Case Reports2024-03-225 citations

Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [177Lu]Lu-DOTA-TATE therapy

Frontiers in Endocrinology2023-10-1110 citations

Lutetium-177 DOTATATE Therapy Is Associated With Biochemical Endocrine Abnormalities in the Immediate Post-Treatment Period

Journal of the Endocrine Society2021-05-011 citations

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma

Frontiers in Endocrinology2021-01-219 citations

SAT-502 Clinical Hypothyroidism Associated with Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma: A Novel Adverse Effect of Peptide Receptor Radionuclide Therapy

Journal of the Endocrine Society2020-04-011 citations

MON-214 Biochemical Abnormalities in Endocrine Function Associated with Lutetium 177-DOTATATE Therapy in Metastatic Pheochromocytoma and Paraganglioma

Journal of the Endocrine Society2020-04-01

Phase 2 trial of Lu-177-DOTATATE in inoperable pheochromocytoma/paraganglioma.

Journal of Clinical Oncology2019-05-205 citations